Molecular aspects of azoles-induced teratogenesis

Expert Opinion on Drug Metabolism and Toxicology

Volumn 6, Issue 4, 2010, Pages 461-482

  Marotta, Francesca ^a   Tiboni, Gian Mario ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Antifungals; Azoles; CYP26; Retinoic acid; Teratogenesis

Indexed keywords

ANTIFUNGAL AGENT; CLOTRIMAZOLE; CYPROCONAZOLE; CYTOCHROME P450; CYTOCHROME P450 ISOENZYME; ECONAZOLE; ENILCONAZOLE; EPOXICONAZOLE; FLUCONAZOLE; FLUSILAZOLE; ITRACONAZOLE; KETOCONAZOLE; LIAROZOLE; MESSENGER RNA; METRONIDAZOLE; MICONAZOLE; MYCLOBUTANIL; N [4 [2 ETHYL 1 (1H 1,2,4 TRIAZOL 1 YL)BUTYL]PHENYL] 2 BENZOTHIAZOLAMINE; PHENYTOIN; PROPICONAZOLE; PYRROLE DERIVATIVE; RETINOIC ACID; STEROL 14ALPHA DEMETHYLASE; TEBUCONAZOLE; TERCONAZOLE; TRANSFORMING GROWTH FACTOR BETA1; TRIADIMEFON; TRIADIMENOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORICONAZOLE;

ABORTION; ANUS ATRESIA; BONE BOWING; CARDIOVASCULAR MALFORMATION; CLEFT PALATE; CONGENITAL HEART MALFORMATION; CONGENITAL HIP DISLOCATION; CRANIOFACIAL SYNOSTOSIS; CRYPTORCHISM; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; EMBRYOPATHY; EMBRYOTOXICITY; ENZYME INHIBITION; FETUS WASTAGE; GENE EXPRESSION; GENE MUTATION; HOMEOSTASIS; HUMAN; HYDRONEPHROSIS; HYPOSPADIAS; JOINT CONTRACTURE; LIMB MALFORMATION; LOW BIRTH WEIGHT; MICROCEPHALY; MICROPHTHALMIA; NONHUMAN; OMPHALOCELE; ORBIT DISEASE; ORBIT HYPOPLASIA; ORGANOGENESIS; PHENOTYPE; PRENATAL DRUG EXPOSURE; PYLORUS STENOSIS; RETINA DETACHMENT; REVIEW; RISK ASSESSMENT; RISK FACTOR; SKELETON MALFORMATION; SPONTANEOUS ABORTION; STEROIDOGENESIS; SYNOSTOSIS; TERATOGENESIS; TERATOGENICITY;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; ANTIFUNGAL AGENTS; AZOLES; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; PREGNANCY;

ANIMALIA;

EID: 77949890691     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425251003592111     Document Type: Review

References (127)

1. Wilson JW. Environment and birth defects (environmental science series). Academic Press, London; 1973
2. Karnofsky DA. Drugs as teratogens in animals and man. Annu Rev Pharmacol 1965;10:447-472
3. Caputo R. Itraconazole (sporanox) in superficial and systemic fungal infections. Expert Rev Anti Infect Ther 2003;1:531-542
4. Zarn JA, Brüschweiler BJ, Schlatter JR. Azole fungicides affect mammalian steroidogenesis by inhibiting sterol 14alpha-demethylase and aromatase. Environ Health Perspect 2003;111:255-261
5. Dix DJ, Gallagher K, Benson WH, et al. A framework for the use of genomics data at the EPA. Nat Biotechnol 2006;24:1108-1111
6. Vanden Bossche H, Ausma J, Bohets H, et al. The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother 2004;48:3272-3278
7. Georgopapadakou NH. Antifungals: mechanism of action and resistance, established and novel drugs. Curr Opin Microbiol 1998;1:547-557
8. Yoshida Y, Aoyama Y, Noshiro M, et al. Sterol 14-demethylase P450 (CYP51) provides a breakthrough for the discussion on the evolution of cytochrome P450 gene superfamily. Biochem Biophys Res Commun 2000;273:799-804
9. Czeizel AE, Kazy Z, Vargha P. A population-based case-control teratological study of vaginal econazole treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol 2003;111:135-140
10. Rosa FW, Baum C, Shaw M. Pregnancy outcomes after first-trimester vaginitis drug therapy. Obstet Gynecol 1987;69:751-755
11. Inman W, Pearce G, Wilton L. Safety of fluconazole in the treatment of vaginal candidiasis. A prescription-event monitoring study, with special reference to the outcome of pregnancy. Eur J Clin Pharmacol 1994;46:115-118
12. Mastroiacovo P, Mazzone T, Botto LD, et al. Prospective assessment of pregnancy outcomes after first-trimester exposure to fluconazole. Am J Obstet Gynecol 1996;175:1645-1650
13. Sorensen HT, Nielsen GL, Olesen C, et al. Risk of malformations and other outcomes in children exposed to fluconazole in utero. Br J Clin Pharmacol 1999;48:234-238
14. Jick SS. Pregnancy outcomes after maternal exposure to fluconazole. Pharmacotherapy 1999;19:221-222
15. Campomori A, Bonati M. Fluconazole treatment for vulvovaginal candidiasis during pregnancy. Ann Pharmacother 1997;31:118-119
16. Nørgaard M, Pedersen L, Gislum M, et al. Maternal use of fluconazole and risk of congenital malformations: a Danish population-based cohort study. J Antimicrob Chemother 2008;62:172-176
17. Bar-Oz B, Moretti ME, Mareels G, et al. G. Reporting bias in retrospective ascertainment of drug-induced embryopathy. Lancet 1999;354:1700-1701
18. Bar-Oz B, Moretti ME, Bishai R, et al. Pregnancy outcome after in utero exposure to itraconazole: a prospective cohort study. Am J Obstet Gynecol 2000;183:617-620
19. De Santis M, Di Gianantonio E, Cesari E, et al. First-trimester itraconazole exposure and pregnancy outcome: a prospective cohort study of women contacting teratology information services in Italy. Drug Saf 2009;32:239-244
20. Rosa FW. Drugs in pregnancy and lactation. Michigan Medicaid Surveillance Study. 1993
21. Kazy Z, Puhó E, Czeizel AE. Population-based case-control study of oral ketoconazole treatment for birth outcomes. Congenit Anom (Kyoto) 2005;45:5-8
22. Carter TC, Druschel CM, Romitti PA, et al. Antifungal drugs and the risk of selected birth defects. Am J Obstet Gynecol 2008;198:191;e1-7
23. Kazy Z, Puhó E, Czeizel AE. Teratogenic potential of vaginal metronidazole treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol 2005;123:174-178
24. Czeizel AE, Kazy Z, Puhó E. Population-based case-control teratologic study of topical miconazole. Congenit Anom (Kyoto) 2004;44:41-45
25. Kazy Z, Puhó E, Czeizel AE. The possible association between the combination of vaginal metronidazole and miconazole treatment and polysyndactyly. Population-based case-control teratologic study. Reprod Toxicol 2005;20:89-94
26. EMEA 2008. Available from: www.emea.europa.eu/htm
27. Shepard TH. Proof of human teratogenicity. Teratology 1994;50:97-98
28. Carey JC, Martinez L, Balken E, et al. Determination of human teratogenicity by the astute clinician method: review of illustrative agents and a proposal of guidelines. Birth Defects Res A Clin Mol Teratol 2009;85:63-68
29. Lopez-Rangel E, Van Allen MI. Prenatal exposure to fluconazole: an identifiable dysmorphic phenotype. Birth Defects Res A 2005;73:919-923
30. Reiners J, Wittfoht W, Nau H, et al. Teratogenesis and pharmacokinetics of cyclophosphamide after drug infusion as compared to injection in the mouse during day 10 of gestation. In: Nau H, Scott WJ Jr, editor, Experimental aspects in vivo and in vitro. Pharmacokinetics in teratogenesis. (Volume 2). CRC Press, Boca Raton; 1987. p. 41-48
31. Nau H. Teratogenic valproic acid concentrations: infusion by implanted minipumps vs conventional injection regimen in the mouse. Toxicol Appl Pharmacol 1985;80:243-250
32. Ornoy A. Valproic acid in pregnancy: how much are we endangering the embryo and fetus? Reprod Toxicol 2009;28:1-10
33. Tiboni GM, Giampietro F. Murine teratology of fluconazole: evaluation of developmental phase specificity and dose dependence. Pediatr Res 2005;58:94-99
34. Tiboni GM, Marotta F, Del Corso A, et al. Defining critical periods for itraconazole-induced cleft palate, limb defects and axial skeletal malformations in the mouse. Toxicol Lett 2006;167:8-18
35. Farag AT, Ibrahim HH. Developmental toxic effects of antifungal flusilazole administered by gavage to mice. Birth Defects Res B Dev Reprod Toxicol 2007;80:12-17
36. Amaral VCS, Nunes GP Jr. Ketoconazole-and Xuconazole-induced embryotoxicity and skeletal anomalies in Wistar rats: a comparative study. Braz Arch Biol Technol 2008;51:1153-1161
37. Amaral VC, Nunes GP Jr. Prednisone reduces ketoconazole-induced skeletal defects in rat fetuses. Arch Toxicol 2009;83:863-871
38. Nishikawa S, Hara T, Miyazaki H, et al. Reproduction studies of KW-1414 in rats and rabbits. Clin Rep 1984;18:1433-1488
39. Machera K. Developmental toxicity of cyproconazole, an inhibitor of fungal ergosterol biosynthesis, in the rat. Bull Environ Contam Toxicol 1995;54:363-369
40. Menegola E, Di Renzo F, Broccia ML, et al. Cleft palate and exposure to an azole derivative: triadimefon. Reprod Toxicol 2009;28:123
41. Menegola E, Broccia ML, Di Renzo F, et al. Relationship between hindbrain segmentation, neural crest cell migration and branchial arch abnormalities in rat embryos exposed to fluconazole and retinoic acid in vitro. Reprod Toxicol 2004;18:121-130
42. Tiboni GM, Marotta F, Castigliego AP. Teratogenic effects in mouse fetuses subjected to the concurrent in utero exposure to miconazole and metronidazole. Reprod Toxicol 2008;26:254-261
43. Taxvig C, Vinggaard AM, Hass U, et al. Endocrine-disrupting properties in vivo of widely used azole fungicides. Int J Androl 2008;31:170-177
44. Augustine-Rauch K. Alternative experimental approaches for interpreting skeletal findings in safety studies. Birth Defects Res B Dev Reprod Toxicol 2007;80:497-504
45. Flick B, Klug S. Whole embryo culture: an important tool in developmental toxicology today. Curr Pharm Des 2006;12:1467-1488
46. Menegola E, Broccia ML, Di Renzo F, et al. Dysmorphogenic effects of some fungicides derived from the imidazole on rat embryos cultured in vitro. Reprod Toxicol 2006;21:74-82
47. Tiboni GM. Second branchial arch anomalies induced by fluconazole, a bis-triazole antifungal agent, in cultured mouse embryos. Res Commun Chem Pathol Pharmacol 1993;79:381-384
48. Menegola E, Broccia ML, Di Renzo F, et al. Antifungal triazoles induce malformations in vitro. Reprod Toxicol 2001;15:421-427
49. Menegola E, Broccia ML, Di Renzo F, et al. Pathogenic pathways in fluconazole-induced branchial arch malformations. Birth Defects Res A Clin Mol Teratol 2003;67:116-124
50. Menegola E, Broccia ML, Di Renzo F, et al. Study on the common teratogenic pathway elicited by the fungicides triazole-derivatives. Toxicol In Vitro 2005;19:737-748
51. Zega G, De Bernardi F, Groppelli S, et al. Effects of the azole fungicide Imazalil on the development of the ascidian Ciona intestinalis (chordata, tunicata): morphological and molecular characterization of the induced phenotype. Aquat Toxicol 2009;91:255-261
52. Pennati R, Groppelli S, Zega G, et al. Toxic effects of two pesticides, imazalil and triadimefon, on the early development of the ascidian Phallusia mammillata (chordata, ascidiacea). Aquat Toxicol 2006;79:205-212
53. Menegola E, Broccia ML, Di Renzo F, et al. In vitro teratogenic potential of two antifungal triazoles: triadimefon and triadimenol. In Vitro Cell Dev Biol Anim 2000;36:88-95
54. Kaufman MH, Bard JBL. The anatomical basis of mouse development. Academic Press, San Diego; 1999
55. Groppelli S, Pennati R, De Bernardi F, et al. Teratogenic effects of two antifungal triazoles, triadimefon and triadimenol, on Xenopus laevis development: craniofacial defects. Aquat Toxicol 2005;73:370-381
56. Nelson DR, Zeldin DC, Hoffman SM, et al. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 2004;14:1-18
57. Choudhary D, Jansson I, Stoilov I, et al. Expression patterns of mouse and human CYP orthologs (families 1-4) during development and in different adult tissues. Arch Biochem Biophys 2005;436:50-61
58. Stoilov I. Cytochrome P450s: coupling development and environment. Trends Genet 2001;17:629-632
59. Libby RT, Kitamoto J, Holme RH, et al. Cdh23 mutations in the mouse are associated with retinal dysfunction but not retinal degeneration. Exp Eye Res 2003;77:731-739
60. McCaffery P, Simons C. Prospective teratology of retinoic acid metabolic blocking agents (RAMBAs) and loss of CYP26 activity. Curr Pharm Des 2007;13:3020-3037
61. Yaffe SJ, Rane A, Sjöqvist F, et al. The presence of a monooxygenase system in human fetal liver microsomes. Life Sci II 1970;9:1189-1200
62. Sun G, Thai SF, Lambert GR, et al. Fluconazole-induced hepatic cytochrome P450 gene expression and enzymatic activities in rats and mice. Toxicol Lett 2006;164:44-53
63. Vinggaard AM, Hnida C, Breinholt V, et al. Screening of selected pesticides for inhibition of CYP19 aromatase activity in vitro. Toxicol In Vitro 2004;14:227-234
64. Colburn DE, Giles FJ, Oladovich D, et al. In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. Hematology 2004;9:217-221
65. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000;38:111-180
66. Niwa T, Shiraga T, Takagi A. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull 2005;28:1805-1808
67. Gyllenhammar I, Eriksson H, Söderqvist A, et al. Clotrimazole exposure modulates aromatase activity in gonads and brain during gonadal differentiation in Xenopus tropicalis frogs. Aquat Toxicol 2009;91:102-109
68. Engelhardt D, Weber MM, Miksch T, et al. The influence of ketoconazole on human adrenal steroidogenesis: incubation studies with tissue slices. Clin Endocrinol (Oxf) 1991;35:163-168
69. AHFS, (American Hospital Formulary Service), Drug Information. American Society of Health-System Pharmacists, Bethesda MD; 1996
70. Iranmanesh A, Ovetsky RM, Lizarralde G, et al. Effect of ketoconazole on the 11-hydroxylation step of adrenal steroidogenesis. South Med J 1987;80:725-728
71. Tiboni GM, Iammarrone E, Giampietro F, et al. Teratological interaction between the bis-triazole antifungal agent fluconazole and the anticonvulsant drug phenytoin. Teratology 1999;59:81-87
72. Schwartz EL, Hallam S, Gallagher RE, et al. Inhibition of all-trans-retinoic acid metabolism by fluconazole in vitro and in patients with acute promyelocytic leukemia. Biochem Pharmacol 1995;50:923-928
73. Vanier KL, Mattiussi AJ, Johnston DL. Interaction of all-trans-retinoic acid with fluconazole in acute promyelocytic leukemia. J Pediatr Hematol Oncol 2003;25:403-404
74. Kirby AJ, Le Lain R, Maharlouie F, et al. Inhibition of retinoic acid metabolising enzymes by 2-(4-aminophenylmethyl)-6-hydroxy-3,4-dihydronaphthalen- 1 (2H)-one and related compounds. J Enzyme Inhib Med Chem 2003;18:27-33
75. Wouters W, van Dun J, Dillen A, et al. Effects of liarozole, a new antitumoral compound, on retinoic acid-induced inhibition of cell growth and on retinoic acid metabolism in MCF-7 human breast cancer cells. Cancer Res 1992;52:2841-2846
76. Pignatello MA, Kauffman FC, Levin AA. Liarozole markedly increases all trans-retinoic acid toxicity in mouse limb bud cell cultures: a model to explain the potency of the aromatic retinoid (E)-4-[2-(5,6,7,8-tetrahydro-5,5,8,8- tetramethyl-2-naphthylenyl)-1-propenyl] benzoic acid. Toxicol Appl Pharmacol 2002;178:186-194
77. Van Wauwe J, Van Nyen G, Coene MC, et al. Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo. J Pharmacol Exp Ther 1992;261:773-779
78. Van Heusden J, Van Ginckel R, Bruwiere H, et al. Inhibition of all-trans-retinoic acid metabolism by R116010 induces antitumour activity. Br J Cancer 2002;86:605-611
79. Pavez Loriè E, Cools M, Borgers M, et al. Topical treatment with CYP26 inhibitor talarozole (R115866) dose dependently alters the expression of retinoid-regulated genes in normal human epidermis. Br J Dermatol 2009;160:26-36
80. Campo-Paysaa F, Marlétaz F, Laudet V, et al. Retinoic acid signaling in development: tissue-specific functions and evolutionary origins. Genesis 2008;46:640-656
81. White JC, Highland M, Kaiser M, et al. Vitamin A deficiency results in the dose-dependent acquisition of anterior character and shortening of the caudal hindbrain of the rat embryo. Dev Biol 2000;220:263-284
82. Niederreither K, Vermot J, Schuhbaur B, et al. Retinoic acid synthesis and hindbrain patterning in the mouse embryo. Development 2000;127:75-85
83. Morriss-Kay GM, Murphy P, Hill RE, et al. Effects of retinoic acid excess on expression of Hox-2.9 and Krox-20 and on morphological segmentation in the hindbrain of mouse embryos. EMBO J 1991;10:2985-2995
84. Armstrong RB, Kim HJ, Grippo JF, Levin AA. Retinoids for the future: investigational approaches for the identification of new compounds. J Am Acad Dermatol 1992;27:S38-42
85. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J 1996;10:940-954
86. Niederreither K, Vermot J, Fraulob V, et al. Retinaldehyde dehydrogenase 2 (RALDH2)-independent patterns of retinoic acid synthesis in the mouse embryo. Proc Natl Acad Sci USA 2002;99:16111-16116
87. Abu-Abed SS, Beckett BR, Chiba H, et al. Mouse P450RAI (CYP26) expression and retinoic acid-inducible retinoic acid metabolism in F9 cells are regulated by retinoic acid receptor gamma and retinoid X receptor alpha. J Biol Chem 1998;273:2409-2415
88. MacLean G, Abu-Abed S, Dollé P, et al. Cloning of a novel retinoic-acid metabolizing cytochrome P450, Cyp26B1, and comparative expression analysis with Cyp26A1 during early murine development. Mech Dev 2001;107:195-201
89. Reijntjes S, Blentic A, Gale E, et al. The control of morphogen signalling: regulation of the synthesis and catabolism of retinoic acid in the developing embryo. Dev Biol 2005;285:224-237
90. Wang Y, Zolfaghari R, Ross AC. Cloning of rat cytochrome P450RAI (CYP26) cDNA and regulation of its gene expression by all-trans-retinoic acid in vivo. Arch Biochem Biophys 2002;401:235-243
91. Tahayato A, Dollé P, Petkovich M. Cyp26C1 encodes a novel retinoic acid-metabolizing enzyme expressed in the hindbrain, inner ear, first branchial arch and tooth buds during murine development. Gene Expr Patterns 2003;3:449-454
92. Reijntjes S, Gale E, Maden M. Expression of the retinoic acid catabolising enzyme CYP26B1 in the chick embryo and its regulation by retinoic acid. Gene Expr Patterns 2003;3:621-627
93. Reijntjes S, Gale E, Maden M. Generating gradients of retinoic acid in the chick embryo: Cyp26C1 expression and a comparative analysis of the Cyp26 enzymes. Dev Dyn 2004;230:509-517
94. de Roos K, Sonneveld E, Compaan B, et al. Expression of retinoic acid 4-hydroxylase (CYP26) during mouse and Xenopus laevis embryogenesis. Mech Dev 1999;82:205-211
95. Emoto Y, Wada H, Okamoto H, et al. Retinoic acid-metabolizing enzyme Cyp26a1 is essential for determining territories of hindbrain and spinal cord in zebrafish. Dev Biol 2005;278:415-427
96. Cañestro C, Postlethwait JH, Gonzàlez-Duarte R, et al. Is retinoic acid genetic machinery a chordate innovation? Evol Dev 2006;8:394-406
97. Abu-Abed S, MacLean G, Fraulob V, et al. Differential expression of the retinoic acid-metabolizing enzymes CYP26A1 and CYP26B1 during murine organogenesis. Mech Dev 2002;110:173-177
98. Uehara M, Yashiro K, Mamiya S, et al. CYP26A1 and CYP26C1 cooperatively regulate anterior-posterior patterning of the developing brain and the production of migratory cranial neural crest cells in the mouse. Dev Biol 2007;302:399-411
99. Santner SJ, Pauley RJ, Tait L, et al. Aromatase activity and expression in breast cancer and benign breast tissue stromal cells. J Clin Endocrinol Metab 1997;82:200-208
100. Buzdar AU, Robertson JF, Eiermann W, et al. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer 2002;95:2006-2016
101. Tiboni GM, Marotta F, Carletti E. Fluconazole alters CYP26 gene expression in mouse embryos. Reprod Toxicol 2009;27:199-202
102. Klug S, Lewandowski C, Wildi L, et al. All-trans retinoic acid and 13-cis-retinoic acid in the rat whole-embryo culture: abnormal development due to the all-trans isomer. Arch Toxicol 1989;63:440-444
103. Di Renzo F, Broccia ML, Giavini E, et al. Citral, an inhibitor of retinoic acid synthesis, attenuates the frequency and severity of branchial arch abnormalities induced by triazole-derivative fluconazole in rat embryos cultured in vitro. Reprod Toxicol 2007;24:326-332
104. Yamamoto Y, Zolfaghari R, Ross AC. Regulation of CYP26 (cytochrome P450RAI) mRNA expression and retinoic acid metabolism by retinoids and dietary vitamin A in liver of mice and rats. FASEB J 2000;14:2119-2127
105. White RJ, Schilling TF. How degrading: Cyp26s in hindbrain development. Dev Dyn 2008;237:2775-2790
106. Dobbs-McAuliffe B, Zhao Q, Linney E. Feedback mechanisms regulate retinoic acid production and degradation in the zebrafish embryo. Mech Dev 2004;121:339-350
107. White RJ, Nie Q, Lander AD, et al. Complex regulation of cyp26a1 creates a robust retinoic acid gradient in the zebrafish embryo. PLoS Biol 2007;5:e304
108. Serpente P, Tümpel S, Ghyselinck NB, et al. Direct crossregulation between retinoic acid receptor {beta} and Hox genes during hindbrain segmentation. Development 2005;132:503-513
109. Taimi M, Helvig C, Wisniewski J, et al. A novel human cytochrome P450, CYP26C1, involved in metabolism of 9-cis and all-trans isomers of retinoic acid. J Biol Chem 2004;279:77-85
110. Papis E, Bernardini G, Gornati R, et al. Gene expression in Xenopus laevis embryos after triadimefon exposure. Gene Expr Patterns 2007;7:137-142
111. Chai Y, Ito Y, Han J. TGF-beta signaling and its functional significance in regulating the fate of cranial neural crest cells. Crit Rev Oral Biol Med. 2003;14:78-88
112. Colakoglu N, Kukner A, Oner J, et al. Effects of high dose retinoic acid on TGF-beta2 expression during pancreatic organogenesis. J Mol Histol 2005;36:413-418
113. Di Renzo F, Corsini E, Broccia ML, et al. Molecular mechanism of teratogenic effects induced by the fungicide triadimefon: study of the expression of TGF-beta mRNA and TGF-beta and CRABPI proteins during rat in vitro development. Toxicol Appl Pharmacol 2009;234:107-116
114. Chen F, Desai TJ, Qian J, et al. Inhibition of Tgf beta signaling by endogenous retinoic acid is essential for primary lung bud induction. Development 2007;134:2969-2979
115. Massa V, Gaudenzi G, Sangiorgio L, et al. Krox20 is down-regulated following triazole in vitro embryonic exposure: a polycompetitor-based assay. Toxicol Lett 2007;169:196-204
116. De S, Turman JE Jr. Krox-20 gene expression: influencing hindbrain-craniofacial developmental interactions. Arch Histol Cytol 2005;68:227-234
117. Borday C, Chatonnet F, Thoby-Brisson M, et al. Neural tube patterning by Krox20 and emergence of a respiratory control. Respir Physiol Neurobiol 2005;149:63-72
118. Warner LE, Mancias P, Butler IJ, et al. Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelinopathies. Nat Genet 1998;18:382-384
119. Chun K, Siegel-Bartelt J, Chitayat D, et al. FGFR2 mutation associated with clinical manifestations consistent with Antley-Bixler syndrome. Am J Med Genet 1998;77:219-224
120. Reardon W. Craniosynostosis. Diagnosis, evaluation and management. J Med Genet 2000;37:727
121. Adachi M, Asakura Y, Tachibana K, et al. Abnormal steroidogenesis in three patients with Antley-Bixler syndrome: apparent decreased activity of 17alpha-hydroxylase, 17,20-lyase and 21-hydroxylase. Pediatr Int 2004;46:583-589
122. Flück CE, Tajima T, Pandey AV, et al. Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat Genet 2004;36:228-230
123. Aleck KA, Bartley DL. Multiple malformation syndrome following fluconazole use in pregnancy: report of an additional patient. Am J Med Genet 1997;72:253-256
124. Csapo A, Dray F, Erdos T. Letter: oestradiol 17beta: inhibitor of placental growth. Lancet 1974;6:51-52
125. Furukawa S, Hayashi S, Usuda K, et al. Histopathological effect of ketoconazole on rat placenta. Vet Med Sci 2008;70:1179-1184
126. Pasanen M, Pellinen P, Stenbäck F, et al. The role of CYP enzymes in cocaine-induced liver damage. Arch Toxicol 1995;69:287-290
127. Tiboni GM, Marotta F, Castigliego AP, et al. Impact of estrogen replacement on letrozole-induced embryopathic effects. Hum Reprod 2009;24(11):2688-2692